Efficacy of Ivermectin in the Treatment of Plane Warts

July 14, 2026 updated by: Sarah Alfoully Ahmed, Al-Azhar University

A Prospective Randomized Controlled Clinical Trial to Evaluate the Efficacy of Oral and Topical Ivermectin in the Treatment of Plane Warts

This study aims to evaluate the efficacy of ivermectin in the treatment of plane warts( flat warts). patients diagnosed with plane warts will be included to assess the clearance ratre of the lesions.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

80

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Asyut, Egypt
        • Department of Dermatology , Al-Azhar university hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria: • Clinical and dermoscopic diagnosis of the plane warts.

  • No prior treatment for warts in the last 4 weeks.
  • Patients of both sex (male - female)
  • Age more than 5 years or weight more than 15 kg.

Exclusion Criteria:

  • • Patients with other types of warts (e.g., common, plantar, genital).

    • History of hypersensitivity or allergy to ivermectin or its components.
    • Patients who have received systemic immunosuppressive therapy within the last 3 months.
    • Presence of chronic skin conditions that may interfere with evaluation (e.g., eczema, psoriasis).
    • Patients with immunodeficiency disorders (e.g., HIV, organ transplant recipients).
    • Pregnant or lactating females.
    • Patients currently on systemic antiviral or immunomodulatory treatment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group1 : topical ivermectin
Patients will receive topical ivermectin cream applied twice daily to plane warts for 3 months
Drug: Ivermectin
An antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol.
Experimental: Group 2 : oral ivermectin
Patients will receive oral ivermectin once weekly for 3 months
Drug: Ivermectin
An antiparasitic medication evaluated for its immunomodulatory and antiviral efficacy in clearing plane warts. it will be administered to patients according to their assigned group protocol.
Placebo Comparator: control group 1
Other: Placebo
Patients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts.
Placebo Comparator: control group 2
Other: Placebo
Patients in the control group will receive placebo,they will undergo standard clinical observation and follow up to monitor the natural course of the plane warts.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
percentage of patients achieving complete clearance of plane warts
Time Frame: 3 months
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Azhar University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2026

Primary Completion (Actual)

June 1, 2026

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

July 14, 2026

First Submitted That Met QC Criteria

July 14, 2026

First Posted (Actual)

July 17, 2026

Study Record Updates

Last Update Posted (Actual)

July 17, 2026

Last Update Submitted That Met QC Criteria

July 14, 2026

Last Verified

July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AZHAR-DERM-2025-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Plane Warts

Clinical Trials on Ivermectin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe